Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 25,482 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 25,482 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $15.03, for a total value of $382,994.46. Following the sale, the insider now owns 135,974 shares of the company’s stock, valued at $2,043,689.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mineralys Therapeutics Stock Down 0.8 %

Shares of Mineralys Therapeutics stock opened at $14.04 on Friday. Mineralys Therapeutics, Inc. has a twelve month low of $5.85 and a twelve month high of $16.91. The company has a fifty day moving average price of $12.90 and a 200 day moving average price of $12.60.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same period in the prior year, the firm earned ($0.31) earnings per share. Equities research analysts expect that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Institutional Trading of Mineralys Therapeutics

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Mineralys Therapeutics during the 3rd quarter valued at $110,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Mineralys Therapeutics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock valued at $116,000 after acquiring an additional 3,732 shares in the last quarter. Bellevue Group AG acquired a new position in shares of Mineralys Therapeutics in the first quarter worth about $119,000. Federated Hermes Inc. boosted its holdings in Mineralys Therapeutics by 100.0% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $140,000 after purchasing an additional 6,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Mineralys Therapeutics during the 2nd quarter valued at approximately $145,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research report on Thursday, October 31st.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.